Preventing Levodopa Induced Dyskinesia in Parkinson's Disease With HMG-CoA Reductase Inhibitors

Conditions:   Parkinson Disease;   Dyskinesia, Drug-Induced Intervention:   Drug: Intravenous Infusion Sponsor:   Oregon Health and Science University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials

Related Links:

Abstract Cordycepin (Cor), one of the major bioactive components of traditional Chinese medicine Cordyceps militaris, has been used in clinical practice for several years. However, the neuroprotective effect of Cor remains unknown. The purpose of the study was to evaluate the neuroprotective effect of Cor on rotenone-induced Parkinson's disease (PD) rat and delineated the possible molecular mechanisms. In vivo, the behavioral tests were performed by the ten-point scale and grid tests, the levels of dopamine and its metabolites in the striatum and the numbers of TH-positive neurons in substantia nigra pars com...
Source: CNS and Neurological Disorders Drug Targets - Category: Drugs & Pharmacology Authors: Tags: CNS Neurol Disord Drug Targets Source Type: research
Publication date: Available online 3 September 2019Source: Neurochemistry InternationalAuthor(s): Zeng-Rui Zhang, Xing-Ru Zhang, Xiao-Qian Luan, Xin-Shi Wang, Wen-Wen Wang, Xiao-Yi Wang, Bei Shao, Cheng-Long XieAbstractProlonged administration of Levodopa (L-dopa) therapy can generate L-dopa–induced dyskinesia (LID). Accumulating evidence indicates that hyper-activation of the dopamine D1 receptor (D1R) and the cAMP signaling cascade in the medium spiny neurons (MSNs) of the striatum are involved in LID. Previous studies have shown that striatal β-arrestin2 overexpression significantly reduces LID severity and h...
Source: Neurochemistry International - Category: Neuroscience Source Type: research
We assessed differential item functioning (DIF) in the Unified Dyskinesia Rating Scale (UDysRS) to evaluate bias risk from the duration of Parkinson's Disease (PD) and duration of dyskinesia.
Source: Parkinsonism and Related Disorders - Category: Neurology Authors: Tags: Short communication Source Type: research
Conditions:   Parkinson Disease;   Dyskinesia, Drug-Induced Intervention:   Drug: Intravenous Infusion Sponsor:   Oregon Health and Science University Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Abstract Dystonia and levodopa-induced dyskinesia (LID) are both hyperkinetic movement disorders. Dystonia arises most often spontaneously, although it may be seen after stroke, injury, or as a result of genetic causes. LID is associated with Parkinson's disease (PD), emerging as a consequence of chronic therapy with levodopa, and may be either dystonic or choreiform. LID and dystonia share important phenomenological properties and mechanisms. Both LID and dystonia are generated by an integrated circuit involving the cortex, basal ganglia, thalamus and cerebellum. They also share dysregulation of striatal choliner...
Source: Neurobiology of Disease - Category: Neurology Authors: Tags: Neurobiol Dis Source Type: research
Abstract Preclinical evidence indicates that mGluR5 is a potential therapeutic target for Parkinson's disease and L-DOPA-induced dyskinesia. However, the mechanisms through which these therapeutic benefits are mediated remain poorly understood. Although the regulatory role of mGluR5 on glutamatergic transmission has been examined in various basal ganglia nuclei, very little is known about the localization and function of mGluR5 in the ventral motor and intralaminar thalamic nuclei, the main targets of basal ganglia output in mammals. Thus, we used immuno-electron microscopy to map the cellular and subcellular loca...
Source: Brain Structure and Function - Category: Neuroscience Authors: Tags: Brain Struct Funct Source Type: research
More News: Carbidopa/Levodopa | Dyskinesia | Parkinson's Disease | Research